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Dear Editor, 
 
Cucurbitacins (Cus) are a class of highly oxidized tetracyclic triterpenoids that confer a 
bitter taste to cucurbits such as cucumber, melon, watermelon, squash, and pumpkin. To date, 
a large number of Cus and Cu-derived compounds have been isolated from the Cucurbitaceae 
family and from other species of the plant (Alghasham, 2013; Shang et al., 2014).  
Cus have a range of biological and pharmacological activities that first attracted attention 
in the 1960s (Chen et al., 2012). Cucurbitacin B (CuB) and Cucurbitacin E (CuE) have been 
particularly widely studied (Lan et al., 2013). Recent reports have demonstrated that CuE has 
growth-inhibitory effects in the proliferation of many cancer cells such as bladder cancer, 
hepatocellular carcinoma, pancreatic cancer, breast cancer, and leukemia (Dong et al., 2010; 
Sörensen et al., 2012). CuB has been shown to have antimicrobial and anti-inflammatory ac-
tivity. However, most reports on CuB focus on its anticancer activity. CuB inhibits the growth 
of human malignant cells, both in vitro and in vivo, and has been shown to be effective 
against breast cancer, head and neck squamous cell carcinoma, pancreatic cancer, hepatocel-
lular carcinoma, osteosarcoma, and myeloid leukemia (Duangmano et al., 2010; Kausar et al., 
2013; Guo et al., 2014a).  
Consequently, natural and semisynthetic Cus are proposed as a promising source for the 
development of new drugs for the prevention and treatment of various cancers. Here, we 
summarize key recent studies that have evaluated the biological and pharmacological activi-
ties of Cu and its derivatives (Table 1).  
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Table 1: Recent studies on Cus and their biological and pharmacological activities 
Key message Reference 
CuB dose dependently inhibited lung cancer cell proliferation by cell cycle inhibition 
and cyclin B1 downregulation. CuB was suggested to be a useful agent in the 
chemotherapy of lung cancer. 
Zhang et al., 
2014 
CuD was shown to have a blocking effect in the G1 phase of the cell cycle in 
nonsmall lung cancer-N6 cells prior to apoptotic cell death. This study provided new 
insight into the mechanisms of proliferation arrest in tumor cells and potentially 
opens new ways of treatment to target tumor growth. 
Jacquot et al., 
2014 
CuE significantly inhibited triple negative breast cancer (TNBC) cell growth by  
inducing cell cycle G2/M phase arrest and apoptosis. Thus, CuE was shown to be  
a viable compound for developing novel TNBC therapeutics. 
Kong et al., 
2014 
Reactive oxygen species (ROS) were shown to mediate CuB-induced DNA dam-
age, G2/M arrest, and apoptosis in K562 leukemia cells. This study provided novel 
mechanisms to better understand the underlying anticancer mechanisms of CuB. 
Guo et al., 
2014b 
CuE inhibited cell proliferation and modulated the expression of cell cycle regula-
tors in cancer cells using A549, Hep3B, and SW480 cells. This study provided a 
novel mechanism that may contribute to the antineoplastic effects of CuE in cancer 
cells. 
Feng et al., 
2014 
This study explored the antiproliferation and cell cycle G2/M arrest induced by CuE 
in colorectal cancer (CRC) cells, and suggested that CuE may have antitumor  
activities in established CRC. 
Hsu et al.,  
2014 
CuB mediated breast tumor growth suppression associated with the inhibition of 
HER2, an oncogenic receptor implicated in HER2/integrin signaling. The results 
suggest novel targets of CuB in breast cancer, both in vitro and in vivo. 
Gupta and  
Srivastava, 
2014 
CuB was shown to have potent chemopreventive activity for prostate cancer, and a 
novel antitumor mechanism of CuB via inhibition of ATP citrate lyase phosphoryla-
tion signaling in human cancer was reported. 
Gao et al.,  
2014 
This study provided new insights into the molecular mechanisms underlying  
CuI-mediated glioblastoma multiforme (GBM) cell death, and suggested CuI as an 
efficacious therapy for patients harboring GBM. 
Yuan et al., 
2014 
Cucurbitacin IIb (CuIIb) was shown to exhibit anti-inflammatory activity through 
modulating multiple cellular behaviors and signaling pathways, leading to the  
suppression of the adaptive immune response. 
Wang et al., 
2014 
CuB showed potent inhibitory activity against hypoxia-inducible factor-1 (HIF-1)  
activation induced by hypoxia in various human cancer cell lines. The paper pro-
vided new insight into the anticancer mechanism of CuB’s activity. 
Ma et al.,  
2014 
Cus were suggested as a new strategy to treat metabolic diseases and implicate 
STAT3 as a new target for the development of functional foods and drugs. 
Seo et al.,  
2014 
CuD extracted from Trichosanthes kirilowii was shown to be a potent therapeutic 
agent for breast cancer, blocking tumor cell proliferation and inducing apoptosis 
through the suppression of STAT3 activity. 
Kim et al.,  
2013 
CuI was suggested to have value as an adjunct chemotherapy agent.  Johnson et al., 
2013 
CuD was shown to initiate immunomodulating activity in macrophages, leading to 
inflammasome activation as well as enhancement of lipopolysaccharide signaling. 
Song et al., 
2013 
CuE inhibited the growth of human breast cancer cells in a dose- and time-
dependent manner, further indicating the potential clinical value of CuE for the  
prevention or treatment of human breast cancer. 
Lan et al.,  
2013 
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Key message Reference 
CuE was shown to induce cell death by a mechanism that is not dependent on 
apoptosis induction, representing a promising anticancer agent for the prevention 
and treatment of human oral squamous cell carcinoma. 
Hung et al., 
2013 
Both CuD and goyazensolide were shown to effectively inhibit the proliferation of 
neurofibromatosis type 2 (NF2)-deficient schwannoma and meningioma cells,  
suggesting that these natural compounds should be further evaluated as potential 
treatments for NF2-related tumors. 
Spear et al., 
2013 
The induction of apoptosis and enhancement of autophagy was shown to contrib-
ute to the anti-inflammatory activity of CuIIa against inflammation-related diseases. 
He et al.,  
2013 
CuE was shown to display anti-inflammatory effects through the suppression of  
nuclear factor (NF)-κB nuclear translocation, leading to a decreased expression of 
tumor necrosis factor (TNF)-α and interleukin (IL)-1β in lipopolysaccharide-
stimulated RAW 264.7 cells. 
Qiao et al.,  
2013 
The physical interaction of CuB with N-acetylcysteine and GSH in a cell-free sys-
tem was demonstrated, suggesting that CuB interacts with and modulates cellular 
thiols to mediate its anticancer effects. 
Kausar et al., 
2013 
Cucurbitacins I, D, and E were shown to present a potent cytotoxic activity toward 
the chondrosarcoma SW 1353 cell line, and are metabolized as sulfate and glucu-
ronide conjugates. 
Abbas et al., 
2013 
The combination of CuB at a relatively low concentration with either of the chemo-
therapeutic agents docetaxel or gemcitabine was shown to have a prominent anti-
proliferative activity against breast cancer cells without increased toxicity. This 
promising combination was suggested for therapeutic trials against breast cancer. 
Aribi et al.,  
2013 
CuB exhibited strong antiproliferative effects against breast cancer cells in a dose-
dependent manner, and was shown to prominently alter the cytoskeletal network of 
breast cancer cells, inducing rapid morphologic changes and improper polymeriza-
tion of the microtubule network. 
Duangmano et 
al., 2012 
CuE was shown to block breast cancer metastasis by suppressing tumor cell mi-
gration and invasion, and was suggested as a potential candidate for treating 
breast cancer metastasis. 
Zhang et al., 
2012 
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